Edition:
United States

Thermo Fisher Scientific Inc (TMO)

TMO on New York Consolidated

156.16USD
26 Sep 2016
Change (% chg)

$-1.50 (-0.95%)
Prev Close
$157.66
Open
$156.98
Day's High
$156.98
Day's Low
$155.61
Volume
1,650,462
Avg. Vol
1,404,691
52-wk High
$160.68
52-wk Low
$117.10

Summary

Name Age Since Current Position

Jim Manzi

64 2007 Independent Chairman of the Board

Marc Casper

48 2009 President, Chief Executive Officer, Director

Stephen Williamson

49 2015 Chief Financial Officer, Senior Vice President

Peter Wilver

56 2015 Executive Vice President, Chief Administrative Officer

Mark Stevenson

53 2014 Executive Vice President, President, Life Sciences Solutions

Seth Hoogasian

61 2006 Senior Vice President, General Counsel, Secretary

Patrick Durbin

49 2015 Senior Vice President, President - Specialty Diagnostics

Thomas Loewald

52 2016 Senior Vice President, Chief Commercial Officer

Daniel Shine

47 2016 Senior Vice President, President, Analytical Instruments

Peter Hornstra

56 2007 Vice President, Chief Accounting Officer

Lars Sorensen

61 2016 Director

Nelson Chai

50 2010 Independent Director

C. Martin Harris

59 2012 Independent Director

Tyler Jacks

55 2009 Independent Director

Judy Lewent

67 2008 Independent Director

Thomas Lynch

61 2009 Independent Director

William Parrett

71 2008 Independent Director

Sperling Sperling

59 2006 Independent Director

Elaine Ullian

68 2001 Independent Director

Kenneth Apicerno

Vice President, Investor Relations

Biographies

Name Description

Jim Manzi

Mr. Jim P. Manzi is an Independent Chairman of the Board of the Company. He was also Chairman of the Board from January 2004 to November 2006. He has been the Chairman of Stonegate Capital, a firm he formed to manage private equity investment activities in technology startup ventures, primarily related to the Internet, since 1995. From 1984 until 1995, he served as the Chairman, President and Chief Executive Officer of Lotus Development Corporation, a software manufacturer that was acquired by IBM Corporation in 1995. We believe that Mr. Manzi is well suited to serve on our Board due to his senior management experience leading Lotus and overall business acumen.

Marc Casper

Mr. Marc N. Casper is President, Chief Executive Officer, Director of the Company. He joined the Company in November 2001 and has been its President and Chief Executive Officer since October 2009. He served as the Company’s Chief Operating Officer from May 2008 to October 2009 and was Executive Vice President from November 2006 to October 2009. Prior to being named Executive Vice President, he was Senior Vice President from December 2003 to November 2006. Prior to joining the Company, Mr. Casper served as president, chief executive officer and a director of Kendro Laboratory Products. Mr. Casper is also a director of U.S. Bancorp. Within the last five years, Mr. Casper was a director of Zimmer Holdings, Inc. We believe that Mr. Casper is well suited to serve on our Board due to his position as Chief Executive Officer of the Company as well as his 19 years in the life sciences/healthcare equipment industry.

Stephen Williamson

Mr. Stephen Williamson is Chief Financial Officer, Senior Vice President of the Company. He was Vice President, Financial Operations of the Company from May 2008 to August 2015. Mr. Williamson joined Thermo Fisher in July 2001 as vice president, European financial operations, based in the U.K., and subsequently served as the finance lead for the Informatics and Services, and Environmental Instruments businesses. He was named vice president of finance for Analytical Technologies in 2006, and two years later became vice president of financial operations for the company. Previously, Mr. Williamson held various finance leadership roles with AlliedSignal/Honeywell in the U.S. and Asia-Pacific. He began his career with Price Waterhouse in London and New York. Mr. Williamson holds a BA in accounting and finance from the University of Wales in the U.K. and is a member of the Institute of Chartered Accountants of England and Wales.

Peter Wilver

Mr. Peter M. Wilver is Executive Vice President, Chief Administrative Officer of the Company. He was Senior Vice President and Chief Financial Officer from November 2006 to August 2015. He was Vice President and Chief Financial Officer from October 2004 to November 2006.

Mark Stevenson

Mr. Mark P. Stevenson is an Executive Vice President, President, Life Sciences Solutions of the Company. Prior to the acquisition of Life Technologies Corporation (“Life Technologies”), Mr. Stevenson was President and Chief Operating Officer of Life Technologies from November 2008 to February 2014 and previously President and Chief Operating Officer of Applied Biosystems, Life Technologies’ predecessor entity, from December 2007 to November 2008.

Seth Hoogasian

Mr. Seth H. Hoogasian is Senior Vice President, General Counsel and Secretary of the Company. Mr. Hoogasian was appointed Senior Vice President in November 2006, Secretary in 2001 and General Counsel in 1992. He was Vice President from 1996 to November 2006.

Patrick Durbin

Mr. Patrick M. Durbin is Senior Vice President, President-Specialty Diagnostics of the Company. He was President of the BioPharma Services business from January 2010 to October 2015.

Thomas Loewald

Mr. Thomas W. Loewald is Senior Vice President, Chief Commercial Officer of the Company. He was President, Analytical Instruments from January 2014 to January 2016 and President, Laboratory Products from January 2012 to January 2014. He was President of the Laboratory Equipment business from August 2008 to December 2011 and was President of the Environmental Instruments business from October 2006 until August 2008.

Daniel Shine

Mr. Daniel P. Shine is Senior Vice President, President, Analytical Instruments of the Company. He was the President of the Chromatography and Mass Spectrometry business from November 2012 to January 2016. He was President of the Chemical Analysis business from July 2011 to November 2012 and President of the Process Instruments business from April 2007 to July 2011.

Peter Hornstra

Mr. Peter E. Hornstra is Vice President, Chief Accounting Officer of the Company. Mr. Hornstra was appointed Vice President in February 2007 and Chief Accounting Officer in January 2001. He was the Corporate Controller from January 1996 to February 2007.

Lars Sorensen

Mr. Lars Rebien Sorensen is Director of Thermo Fisher Scientific Inc. He has been President and Chief Executive Officer of Novo Nordisk A/S, a global healthcare company with a leading position in diabetes care, since November 2000. He has held various senior management roles at Novo Nordisk since joining the company in 1982. Mr. Sørensen also currently serves as a member of the supervisory board of Bertelsmann AG, a worldwide media company based in Germany. Within the last five years, he was a director of ZymoGenetics Inc., Dong Energy A/S and Danmarks Nationalbank.

Nelson Chai

Mr. Nelson J. Chai is an Independent Director of the Company. He was President of CIT Group Inc., a bank holding company that provides lending, advisory and leasing services to small and middle market businesses, from August 2011 to December 2015. He joined CIT Group in June 2010 as Executive Vice President, Chief Administrative Officer and head of strategy. Previously, he was President, Asia-Pacific for Bank of America Corporation beginning in December 2008, and Executive Vice President and Chief Financial Officer of Merrill Lynch & Co., a financial services firm, from December 2007 to December 2008. Prior to that Mr. Chai was Executive Vice President and Chief Financial Officer of NYSE Euronext, a stock exchange group, from March 2006 to December 2007, and Chief Financial Officer of Archipelago Holdings, L.L.C., an electronic stock exchange, from June 2000 to March 2006. We believe that Mr. Chai is well suited to serve on our Board due to his many years of experience in finance and accounting.

C. Martin Harris

Dr. C. Martin Harris, M.D., is an Independent Director of the Company. Dr. Harris has been the Chief Strategy Officer of The Cleveland Clinic Foundation, a multi-specialty academic medical center, and since 1996, he has been the Chief Information Officer and Chairman of the Information Technology Division of and a Staff Physician for The Cleveland Clinic Hospital and The Cleveland Clinic Foundation Department of General Internal Medicine. Additionally, since 2000, he has been Executive Director of e-Cleveland Clinic, a series of e-health clinical programs offered over the Internet. Dr. Harris is also a director of HealthStream Inc. and Invacare Corporation. We believe that Dr. Harris is well suited to serve on our Board due to his experience in the healthcare industry as a physician and leader of healthcare organizations and also his expertise in the use of information technology in the healthcare industry.

Tyler Jacks

Dr. Tyler Jacks, Ph.D. is an Independent Director of the Company. He is the David H. Koch Professor of Biology at the Massachusetts Institute of Technology (MIT) and director of the David H. Koch Institute for Integrative Cancer Research. He joined the MIT faculty in 1992 and was director of its Center for Cancer Research from 2001 to 2008. Since 2002, Dr. Jacks has been an investigator with the Howard Hughes Medical Institute. Dr. Jacks is also a director of Amgen Inc. We believe that Dr. Jacks is well suited to serve on our Board due to his experience as a cancer researcher and member of multiple scientific advisory boards in biotechnology companies, pharmaceutical companies and academic institutions.

Judy Lewent

Ms. Judy C. Lewent is an Independent Director of the Company. She was Chief Financial Officer of Merck & Co., Inc., a global pharmaceutical company, from 1990 until her retirement in 2007. She was also Executive Vice President of Merck from February 2001 through her retirement and had additional responsibilities as President, Human Health Asia from January 2003 until July 2005, when she assumed strategic planning responsibilities for Merck. Ms. Lewent is also a director of Motorola Solutions, Inc. and GlaxoSmithKline plc, and within the last five years was a director of Dell, Inc. We believe that Ms. Lewent is well suited to serve on our Board due to her many years of global experience in finance and the pharmaceutical industry.

Thomas Lynch

Mr. Thomas J. Lynch is an Independent Director of the Company. He is Chairman and Chief Executive Officer of TE Connectivity Ltd. (formerly Tyco Electronics Ltd.), a global provider of engineered electronic components, network solutions, undersea telecommunication systems and specialty products. He joined Tyco International in 2004 as President of Tyco Engineered Products and Services and was appointed Chief Executive Officer in January 2006, when Tyco Electronics was formed and later became an independent, separately traded entity and was appointed Chairman in January 2013. Mr. Lynch is also a director of TE Connectivity Ltd. and Cummins Inc. We believe that Mr. Lynch is well suited to serve on our Board due to his experience as Chief Executive Officer of a comparably-sized global company.

William Parrett

Mr. William G. Parrett is an Independent Director of the Company. He served as Chief Executive Officer of Deloitte Touche Tohmatsu, a global accounting firm. Mr. Parrett joined Deloitte in 1967, and served in a series of roles of increasing responsibility. Mr. Parrett serves as a director of the Blackstone Group LP, Eastman Kodak Company and UBS AG, and is chairman of their Audit Committees. Within the last five years, Mr. Parrett was a director of iGate Corporation. Mr. Parrett is a Certified Public Accountant (New York) with an active license. We believe that Mr. Parrett is well suited to serve on our Board due to his experience as Chief Executive Officer of Deloitte Touche Tohmatsu, which demonstrates his leadership capability and extensive knowledge of complex financial and operational issues.

Sperling Sperling

Mr. Scott M. Sperling is an Independent Director of the Company. Prior to the merger of Thermo Electron Corporation and Fisher Scientific International Inc., he was a director of Fisher Scientific from January 1998 to November 2006. He has been employed by Thomas H. Lee Partners, L.P., a leveraged buyout firm, and its predecessor, Thomas H. Lee Company, since 1994. Mr. Sperling currently serves as Co-President of Thomas H. Lee Partners, L.P. Mr. Sperling is also a director of iHeartMedia, Inc. and The Madison Square Garden Company, and within the last five years was a director of Warner Music Group Corp. We believe that Mr. Sperling is well suited to serve on our Board due to his experience in acquisitions and finance.

Elaine Ullian

Ms. Elaine S. Ullian is an Independent Director of the Company. She was the President and Chief Executive Officer of Boston Medical Center, a 550-bed academic medical center affiliated with Boston University, from July 1996 to her retirement in January 2010. Ms. Ullian is also a director of Vertex Pharmaceuticals, Inc. and Hologic Inc. We believe that Ms. Ullian is well suited to serve on our Board due to her experience as Chief Executive Officer of Boston Medical Center, a healthcare provider similar to many of the Company’s customers.

Kenneth Apicerno